Please Wait.....
Report
GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends
Company Report I 2025-02-27 I 147 Pages I Quaintel Research
Report Summary
GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of GSK plc's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about GSK plc, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses GSK plc's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of GSK plc's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers GSK plc's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares GSK plc's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by GSK plc, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline and French firm. GSK aims to deliver impactful medicines, vaccines, and treatments, positively affecting the lives of 2.5 billion people by 2030. It invest heavily in research and development, utilizing advancements like AI and robotics for faster production. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of 69 billion, the eighth largest on the London Stock Exchange. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSKs vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others.
GSK plc in the News:-
- 15-Feb-2025 - Penmenvy, GSKs 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
- 31-Jan-2025 - European Commission authorises ViiV Healthcares long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
- 28-Jan-2025 - Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
- 28-Jan-2025 - Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
- 27-Jan-2025 - GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
Scope
Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
Comprehensive Understanding of the GSK plc's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company GSK plc:
GSK plc Porter's Five Forces Analysis
GSK plc VRIO Analysis
GSK plc BCG Analysis
GSK plc Segmentation, Targeting and Positioning (STP) Analysis
GSK plc Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
GSK plc - Key Company Facts 9
GSK plc - Company Description 10
GSK plc - Top Executives 11
GSK plc- Head Office & Locations 13
Head Office - Country 13
GSK plc - Products and Services 14
Products 14
Services 15
GSK plc - Corporate Strategy 18
GSK plc - Business Description 25
Vaccines 26
Specialty Medicines 26
General Medicines 27
GSK plc - ESG Spotlight 28
Environment 28
Social 29
Corporate Governance 30
GSK plc - SWOT Analysis 31
Overview 31
Strengths 33
Weaknesses 36
Opportunities 38
Threats 41
GSK plc - PESTLE Analysis 42
Overview 42
Political Factors 44
Economic Factors 45
Social Factors 47
Technological Factors 49
Legal Factors 51
Environmental Factors 52
GSK plc - Chapter1 name 54
Heading1 54
Heading2 54
GSK plc - Chapter1 name 55
Heading1 55
Heading2 55
GSK plc- Chapter1 name 56
Heading1 56
Heading2 56
GSK plc - Financial Deep Dive 57
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 57
Profit and Loss Statement 59
Summary of Profit and Loss Statement 59
Balance Sheet 61
Summary of Balance Sheet 61
Cash Flow Statement 63
Summary of Cash Flow Statement 63
Key Financial Ratio Analysis 65
GSK plc - Ratio Charts 66
Activity Ratio Charts 66
Growth Ratios Charts 67
Leverage Ratio Charts 68
Liquidity Ratio Charts 69
Profitability Ratio Charts 70
Competing Players 71
Snapshot of Competing Players 72
Roche Holding AG 72
Key Company Facts 72
Company Description 72
Johnson & Johnson 73
Key Company Facts 73
Company Description 73
Novartis AG 74
Key Company Facts 74
Company Description 74
Pfizer Inc. 75
Key Company Facts 75
Company Description 75
Merck & Co., Inc. 76
Key Company Facts 76
Company Description 76
GSK plc - In the News 77
15-Feb-2025 - Penmenvy, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY 77
31-Jan-2025 - European Commission authorises ViiV Healthcare's long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents 79
28-Jan-2025 - Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP 80
28-Jan-2025 - Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP 82
27-Jan-2025 - GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research 84
27-Jan-2025 - GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency 85
10-Jan-2025 - GSK's Shingrix new prefilled syringe presentation accepted for review by US FDA 86
23-May-2024 - Statement: Zantac (ranitidine) litigation - Valadez and Williams cases 86
21-May-2024 - GSK announces positive results from phase III severe asthma trials of depemokimab 86
24-Apr-2024 - US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer 89
17-Apr-2024 - EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments 92
17-Apr-2024 - New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade 94
16-Apr-2024 - GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA 96
16-Mar-2024 - Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer 98
07-Mar-2024 - GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma 100
06-Mar-2024 - ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges 102
29-Feb-2024 - GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director 105
28-Feb-2024 - ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV 107
GSK plc - Key Deals 109
24-Feb-2025 - GSK completes acquisition of IDRx, Inc. 109
13-Jan-2025 - GSK enters agreement to acquire IDRx, Inc. 110
05-Dec-2024 - GSK and Zhifei revise and extend strategic vaccine collaboration in China 112
29-Oct-2024 - GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline 112
29-Oct-2024 - GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline 114
21-Oct-2024 - GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease 114
16-May-2024 - GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) 117
15-Feb-2024 - GSK completes acquisition of Aiolos Bio 119
09-Jan-2024 - GSK enters agreement to acquire Aiolos Bio 119
20-Dec-2023 - GSK enters exclusive license agreement with Hansoh for HS-20093 122
31-Oct-2023 - GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen 124
09-Oct-2023 - GSK and Zhifei announce exclusive strategic vaccine partnership in China 127
28-Jun-2023 - GSK completes acquisition of BELLUS Health 130
18-Apr-2023 - GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health 132
30-Mar-2023 - GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection 135
13-Dec-2022 - GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets 138
Appendix 141
Definitions 141
SWOT Analysis 141
PESTLE Analysis 141
Value Chain Analysis 141
ESG Spotlight 141
Financial Deep Dive 141
Financial Ratios - 142
Activity Ratios 142
Growth Ratios 143
Leverage Ratios 144
Liquidity Ratios 145
Market Ratios 146
Profitability Ratios 146
Research Methodology 147
Disclaimer 148
Contact Us 148
Tables
Table 1: GSK plc - Company Facts
Table 2: GSK plc - Digital Presence
Table 3: GSK plc - Top Executives
Table 4: GSK plc - Products
Table 5: GSK plc - Services
Table 6: GSK plc - Share Price Trend - Feb-2024 to Feb-2025
Table 7: GSK plc - Ratio Analysis - 2020-2023
Table 8: GSK plc - Competing Players
Table 9: Competing Players - Roche Holding AG - Key Company Facts
Table 10: Competing Players - Johnson & Johnson - Key Company Facts
Table 11: Competing Players - Novartis AG - Key Company Facts
Table 12: Competing Players - Pfizer Inc. - Key Company Facts
Table 13: Competing Players - Merck & Co., Inc. - Key Company Facts
Charts
Figure 1: GSK plc- SWOT Analysis
Figure 2: GSK plc - PESTLE Analysis
Figure 3: GSK plc - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 4: GSK plc - Profit and Loss Statement - 2021-2024
Figure 5: GSK plc - Balance Sheet - 2021-2024
Figure 6: GSK plc - Cash Flow Statement 2021-2024
Figure 7: GSK plc - Activity Ratio Charts
Figure 8: GSK plc - Growth Ratio Charts (Value %)
Figure 9: GSK plc - Leverage Ratio Charts
Figure 10: GSK plc - Liquidity Ratio Charts
Figure 11: GSK plc - Profitability Ratio Charts (Value %)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security